Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
Approved For Marketing
1
12.5%
已完成
6
75.0%
终止
1
12.5%
暂无批准数据
- The global precision biotics market was valued at USD 4.90 billion in 2025 and is projected to reach approximately USD 17.46 billion by 2035, expanding at a CAGR of 13.55%. - The probiotics segment dominated with a 34% market share in 2025, while precision microbiome therapeutics is expected to grow at the fastest CAGR of 18.6% through 2035. - North America led the market with a 39% revenue share in 2025, while Asia Pacific is forecast to grow at the strongest regional CAGR of 17.3%. - Advances in AI, next-generation sequencing, and CRISPR-based microbial engineering are accelerating strain discovery and clinical validation of targeted microbiome interventions.
- The global microbiome oncology market is forecast to grow from USD 353.20 million in 2026 to USD 1.94 billion by 2031, representing a compound annual growth rate of 40.7%. - Scientific evidence increasingly links gut microbiota composition to immune regulation, inflammation, and patient response to immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4. - Melanoma and colorectal cancer dominate research focus, with next-generation sequencing leading as the primary technology and immunotherapy enhancement as the key application. - Key players include Seres Therapeutics, Vedanta Biosciences, MaaT Pharma, Enterome, and 4D Pharma, with multiple pipeline candidates in Phase I through Phase III clinical trials.
- The global microbiome therapeutics market reached USD 288.8 million in 2025 and is projected to hit USD 4,023.1 million by 2034, growing at a CAGR of 34.90%. - Seres Therapeutics achieved the first positive pivotal clinical results for a targeted microbiome drug candidate, SER-109, which received FDA Breakthrough Therapy and Orphan Drug Designations for recurrent C. difficile infection. - Enterome raised USD 19 million in Series E funding in June 2025 to advance OncoMimic-based cancer immunotherapies and inflammatory bowel disease therapies into phase I trials. - The field is shifting from traditional fecal microbiota transplants toward defined bacterial consortia and engineered "designer bacteria" that function as living drug factories inside the body.
- Takeda Pharmaceutical will lay off 247 employees at its Cambridge location and 387 at other U.S. sites as part of a comprehensive restructuring plan approved by the board on March 25. - The restructuring aims to save more than $1.25 billion annually by 2028 while costing over $940 million this fiscal year, with resources redirected toward late-stage drug development. - The company plans to prioritize strategic investments in its pipeline, including upcoming launches of oveporexton, rusfertide, and zasocitinib. - Despite the layoffs beginning July 1, Takeda maintains approximately 700 open positions globally, with nearly 300 available in Massachusetts.
- Seres Therapeutics published two studies in Nature Medicine and Journal of Infectious Diseases demonstrating VOWST's mechanism of action through microbiome restoration and metabolite production that inhibits C. difficile growth. - The research confirmed that higher VOWST dosing enhances therapeutic bacterial engraftment and significantly alters intestinal microbiome composition, including increased secondary bile acids and fatty acids. - Data from the ECOSPOR IV Phase 3 trial showed consistent disease etiology and VOWST efficacy across both first and multiply recurrent CDI patient populations. - The findings validate Seres' MbTx platform and support development of SER-155, which reduced bloodstream infections by 77% in Phase 1b trials for stem cell transplant patients.
- PsiThera closed a $47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance oral medicines targeting immune and inflammatory diseases. - The company appointed biotech veteran Eric Shaff as CEO, who previously led Seres Therapeutics' approval of VOWST, the first oral FDA-approved microbiome therapeutic. - PsiThera's QUAISAR platform integrates quantum chemistry, molecular dynamics, and AI to develop oral drugs for TNF superfamily targets traditionally accessible only to biologics. - The platform demonstrated rapid drug discovery capabilities, advancing from hit identification to lead optimization in just four months for their lead program.
- Vedanta Biosciences will lay off nearly 20% of its staff after experimental microbiome therapy VE202 failed to meet its primary endpoint in a Phase 2 ulcerative colitis study. - The VE202 treatment, licensed by Johnson & Johnson in 2015, was not significantly better than placebo at improving disease signs on endoscopic examination after eight weeks of treatment. - The company will now focus resources on VE303, a microbiome therapy in Phase 3 testing for recurrent C. diff infections, and a preclinical therapy for antibiotic-resistant bacterial infections. - The failure adds to mounting evidence of challenges in developing microbiome-based therapies for inflammatory bowel disease, following similar setbacks from competitors like Seres Therapeutics.
- Seres Therapeutics has appointed Thomas DesRosier and Marella Thorell as co-CEOs following Eric Shaff's departure after a decade leading the company. - The company is actively engaging with multiple parties for business development partnerships to secure additional capital for advancing SER-155, which showed a 77% relative risk reduction in bloodstream infections. - SER-155 has received FDA Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. - The leadership transition comes as Seres focuses on expanding SER-155's potential across multiple medically vulnerable patient populations beyond transplant recipients.
- Research demonstrates that gut microbiota significantly influences cancer treatment outcomes, with disrupted gut bacteria associated with resistance to immunotherapies and chemotherapy. - Clinical trials show promising results for microbiome-targeted interventions, including fecal microbiota transplantation achieving 66.7% progression-free survival in renal cell carcinoma patients and 80% overall response rate in lung cancer. - Multiple biotechnology companies are developing novel treatments that leverage gut bacteria, including Enterome's OncoMimics peptides and MaaT Pharma's microbiome ecosystem therapy, both advancing through Phase 2 and 3 trials. - Antibiotic use poses significant risks to cancer patients by reducing microbiome diversity and impairing immune responses, with studies showing increased death risk and reduced immunotherapy effectiveness.
- Seres Therapeutics will present new biomarker data at ASCO 2025 showing SER-155's potential to promote immune reconstitution following allogeneic hematopoietic stem cell transplantation. - Post hoc analyses from the Phase 1b study revealed significantly higher levels of IL-7 cytokine and increased CD4+ T cell frequency in patients treated with SER-155 compared to placebo. - The findings support SER-155's dual mechanism of reducing bloodstream infections by 77% while promoting essential T-cell recovery for long-term patient outcomes. - The company plans to submit a Phase 2 trial protocol to the FDA in the coming weeks and is actively seeking development partners.
